1. The prostacyclin-thromboxane A2 balance: Pathophysiological and therapeutic implications;Bunting;Br. Med. Bull.,1983
2. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b.f)-thepin-5,5-dioxide (L-640,035);Chan;J. Pharmacol. Exp. Ther.,1984
3. Platelet TXA2 synthetase inhibition and TXA2/prostaglandin endoperoxide receptor blockade combined in one molecule (R 68070);De Clerck;Thromb. Haemostas.,1987
4. Spectral studies on structure-activity relationships of thromboxane synthase inhibitors;Hecker;European J. Biochem.,1986
5. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs;Imamoto;J. Cardiovasc. Pharmacol.,1986